FindMyKOL

Gary Macvicar, MD

Basic profile

Illinois CancerCare

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPeoria, IL · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Gary Macvicar is an Oncology physician affiliated with Illinois CancerCare. OpenAlex indexes 47 publications with 3,735 citations (h-index 20).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
47publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

3,735citations

Citations across these publications.

20h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
8companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Merck & Co.
    Program year20258 paymentsResearch
    $783,908
  • Bristol Myers Squibb
    Program year20252 paymentsResearch
    $197,743
  • Daiichi Sankyo
    Program year20257 paymentsResearch
    $17,522
All 31 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    52.2%
    PD-1 inhibitor20%
    Pembrolizumab56%Nivolumab44%
    Part B, office-administered≥20 patients
    Nucleoside Metabolic Inhibitor12.4%
    Azacitidine94%Fluorouracil4%Gemcitabine hydrochloride2%
    Part B, office-administered≥20 patients

    + 13 more classes in this area

  • Blood & clotting

    25.5%
    Iron, parenteral preparations21.7%
    Ferric carboxymaltose100%
    Part B, office-administered≥26 patients
    Erythropoiesis-stimulating Agent3.7%
    Darbepoetin alfa63%Epoetin alfa37%
    Part B, office-administered≥14 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    12.5%
    Substance P/Neurokinin-1 Receptor Antagonist6.2%
    Aprepitant100%
    Part B, office-administered≥25 patients
    Other antiemetics2.9%
    Fosaprepitant100%
    Part B, office-administered≥11 patients

    + 5 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”